Back

Early-onset atrial fibrillation is a risk marker for cardiomyopathy: genetic insights from the UK Biobank

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Rhythm control in atrial fibrillation: prognostic and therapeutic implications Genetic Causes ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Quim Bech Vilaseca

Copenhagen (Denmark)

8 More presentations in this session

Presentation thumbnail
Cluster-specific predictors of early rhythm control in contemporary European cohort of patients with atrial fibrillation: The EHRA-PATHS Project
Doctor M. Mihajlovic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Impact of rhythm control strategy on outcomes in patients with first diagnosed atrial fibrillation in an 11-year real-world registry
Doctor C. Salbach (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Atrial function after cardioversion in patients with persistent atrial fibrillation
Doctor K. Noda (Sendai, JP)
Abstract Slides Video
Presentation thumbnail
Sinus rhythm maintenance and the changes of echocardiographic parameters in patients with late persistent atrial fibrillation at 6 months after direct current cardioversion
Doctor Y. Skybchyk (Kiev, UA)
Abstract Slides Video
Presentation thumbnail
H558R: a common polymorphism may modify the efficacy and toxicity of flecainide in maintaining sinus rhythm; a cohort study.
Mr M. Trincado Ave (Santiago de Compostela, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Rhythm control in atrial fibrillation: prognostic and therapeutic implications

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Whole exome sequencing in young atrial fibrillation patients
thumbnail
Congress Presentation
Sequencing in over 120,000 cases unveils the rare coding variant architecture of atrial fibrillation
thumbnail
Congress Presentation
Markers of atrial myopathy in the UK Biobank: prevalence, consequences, and risk stratification

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources